Clinical trials: Stage II Hepatocellular Carcinoma AJCC v8
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205 (BMS-986205) when given together with nivolumab and how well it works as first or second line therapy in treating patients with liver…
- Conditions
- Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT03695250
- Testing
- IDO1 Inhibitor BMS-986205, Nivolumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Edward Kim
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
This phase II trial studies the efficacy and safety of systemic induction of mFOLFIRINOX, followed by hepatic arterial infusion (HAI) floxuridine-dexamethasone administered concurrently with systemic mFOLFIRI in treating patients…
- Conditions
- Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT04251715
- Testing
- Dexamethasone, Floxuridine, Implanted Medical Device
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- OHSU Knight Cancer Institute
Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
This phase II trial tests whether regorafenib and durvalumab work to shrink tumors in patients with high-risk liver cancer. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT05194293
- Testing
- Durvalumab, Regorafenib
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Academic and Community Cancer Research United